novel
coronaviru
identifi
etiolog
agent
sever
acut
respiratori
syndrom
sar
rapidli
identifi
antisar
drug
avail
clinic
use
screen
set
compound
includ
antivir
drug
alreadi
wide
use
report
proteas
inhibitor
nelfinavir
strongli
inhibit
replic
sar
coronaviru
sarscov
nelfinavir
inhibit
cytopath
effect
induc
sarscov
infect
express
viral
antigen
much
lower
infect
cell
treat
nelfinavir
untreat
infect
cell
quantit
rtpcr
analysi
show
nelfinavir
could
decreas
product
virion
vero
cell
experi
variou
time
drug
addit
reveal
nelfinavir
exert
effect
entri
step
postentri
step
sarscov
infect
result
suggest
nelfinavir
examin
clinic
treatment
sar
potenti
good
lead
compound
design
antisar
drug
sever
acut
respiratori
syndrom
sar
emerg
diseas
first
report
guangdong
provinc
peopl
republ
china
novemb
sinc
sar
spread
countri
result
death
respiratori
distress
syndrom
overal
estim
case
fatal
reach
report
mortal
rate
peopl
older
year
could
high
sever
group
includ
author
isol
novel
coronaviru
sar
patient
shown
sarscov
satisfi
koch
postul
causationit
consist
isol
patient
suffer
sar
isol
viru
reproduct
diseas
nonhuman
primat
inocul
presenc
specif
antibodi
respons
viru
sar
patient
artifici
infect
primat
etiolog
role
sar
wide
accept
outbreak
sar
sever
countri
led
search
activ
antivir
compound
vaccin
diseas
although
result
mani
clinic
experi
report
consensu
treatment
reach
date
therapeut
protocol
steroid
ribavirin
wide
use
empir
outset
epidem
use
steroid
sar
seem
benefici
whenev
appropri
appli
howev
optim
time
dosag
durat
treatment
yet
determin
hand
administr
ribavirin
appar
reduc
either
rate
intratrach
intub
mortal
moreov
signific
toxic
hemolyt
anemia
attribut
ribavirin
preliminari
trial
vitro
data
suggest
possibl
treat
sar
interferon
agent
includ
glycyrrhizin
convalesc
plasma
requir
studi
well
establish
case
infect
combin
antivir
drug
make
possibl
establish
better
protocol
treatment
sar
identifi
antisar
drug
avail
clinic
use
rapidli
possibl
screen
set
compound
includ
antivir
drug
alreadi
human
clinic
use
found
nelfinavir
wide
use
proteas
inhibitor
could
inhibit
sarscov
replic
effici
result
suggest
nelfinavir
examin
clinic
treatment
sar
cell
cultur
viru
vero
cell
maintain
dulbecco
modifi
eagl
medium
supplement
fb
glutaminepenicillinstreptomycin
solut
co
humidifi
air
strain
sarscov
isol
sar
patient
admit
clinic
centr
frankfurt
univers
strain
use
experi
assess
antivir
activ
drug
compound
screen
set
compound
screen
consist
drug
follow
nelfinavir
saquinavir
ritonavir
lopinavir
indinavir
vmipii
glycyrrhizin
glycyrrhet
acid
cardran
sulfat
cytopath
effect
assay
sarscov
inocul
monolay
vero
cell
plate
multipl
infect
moi
plate
incub
co
day
cpe
well
observ
immunofluoresc
assay
vero
cell
plate
infect
sarscov
moi
infect
cell
fix
methanol
h
infect
incub
room
temperatur
h
dilut
serum
sampl
sar
patient
wash
pb
cell
incub
antihumanigg
antibodi
conjug
fitc
min
room
temperatur
cell
wash
pb
mount
buffer
glycerol
coverslip
view
fluoresc
microscop
rna
extract
realtim
rtpcr
assay
sarscov
rna
cultur
supernat
purifi
isogen
nippongen
accord
manufactur
protocol
quantif
sarscov
rna
perform
realtim
rtpcr
primer
probe
follow
agctacgagcaccagacacc
actttgggcattccccttt
tcgaaa
ttaagagtgccaagaaatttgacacttt
fluoresc
intens
gener
probe
detect
sequenc
detector
system
appli
biosystem
mtt
assay
vero
cell
plate
infect
sarscov
moi
h
cultur
cell
incub
h
presenc
mgml
tetrazolium
bromid
mtt
formazan
crystal
dissolv
n
hclisopropyl
alcohol
acid
isopropanol
absorb
nm
measur
refer
wavelength
nm
timeofaddit
experi
drug
includ
nelfinavir
ad
cultur
vero
cell
time
infect
h
infect
sampl
process
quantit
rtpcr
assay
immunofluoresc
assay
h
infect
cytopath
effect
infect
cell
analyz
h
infect
entri
inhibit
assay
vero
cell
pretreat
drug
h
sarscov
inocul
moi
cell
virus
incub
h
wash
pb
three
time
subsequ
infect
cell
lyse
isogen
nippongen
rna
purifi
accord
manufactur
protocol
extract
rna
sampl
subject
realtim
rtpcr
analysi
quantif
sarscov
rna
describ
load
control
normal
ribosom
rna
quantifi
primer
probe
follow
gtaacccgttgaaccccatt
ccatccaatcggtagtagcg
tgcgtt
gattaagtccctgccctttgta
screen
chemic
librari
found
nelfinavir
could
inhibit
sarscov
replic
vero
cell
nelfinavir
clearli
inhibit
cytopath
effect
cpe
induc
infect
sarscov
fig
also
examin
replic
sarscov
immunofluoresc
assay
ifa
serum
sampl
patient
sar
express
viral
antigen
much
lower
infect
cell
treat
nelfinavir
untreat
infect
cell
fig
furthermor
assess
effect
nelfinavir
product
virion
nelfinavir
significantli
block
product
virion
reveal
quantit
rtpcr
fig
use
mtt
assay
determin
concentr
compound
reduc
cell
viabil
cc
concentr
compound
requir
inhibit
cpe
control
valu
ec
select
index
si
nelfinavir
inhibit
sarscov
replic
nontox
dose
approxim
si
inhibitor
proteas
ritonavir
lopinavir
saquinavir
indinavir
affect
replic
sarscov
tabl
result
reveal
nelfinavir
activ
inhibit
sarscov
replic
nelfinavir
inhibit
sarscov
replic
postentri
entri
step
disclos
step
nelfinavir
affect
viru
life
cycl
perform
timeofaddit
experi
replic
sarscov
nelfinavir
significantli
inhibit
sarscov
replic
use
infect
fig
b
drug
ad
time
infect
h
infect
still
abl
block
cpe
induc
sarscov
infect
fig
addit
nelfinavir
variou
time
inhibit
express
viral
antigen
vero
cell
shown
ifa
fig
nelfinavir
block
product
virion
use
treat
cell
time
infect
h
infect
fig
proteas
inhibitor
includ
ritonavir
effect
replic
sarscov
cc
cytotox
concentr
compound
reduc
cell
viabil
mean
standard
error
three
assay
calcul
drug
fig
b
result
indic
target
nelfinavir
may
involv
postentri
step
sarscov
replic
investig
whether
nelfinavir
affect
effici
virion
entri
quantifi
copi
number
sarscov
rna
vero
cell
immedi
entri
virion
realtim
rtpcr
reveal
nelfinavir
affect
entri
step
sarscov
infect
fig
consist
assumpt
nelfinavir
block
postentri
step
sarscov
replic
mechan
underli
inhibitori
action
nelfinavir
sarscov
replic
remain
identifi
main
proteinas
sarscov
one
molecul
express
infect
import
role
viral
replic
effect
nelfinavir
main
proteinas
activ
investig
clone
express
purifi
sarscov
main
proteinas
order
examin
effect
nelfinavir
enzym
preliminari
studi
indic
activ
main
proteinas
block
partial
data
shown
impli
nelfinavir
may
interact
molecul
main
proteinas
fulli
inhibit
sarscov
replic
nelfinavir
safe
wide
use
inhibitor
proteas
strong
vivo
activ
hivinfect
patient
nelfinavir
gener
use
combin
antiretrovir
medic
part
highli
activ
antiretrovir
regimen
haart
use
manner
patient
naiv
antiretrovir
therapi
plasma
hiv
rna
level
limit
detect
associ
approxim
increas
mm
lymphocyt
month
therapi
common
side
effect
nelfinavir
mild
diarrhea
observ
patient
nelfinavir
well
toler
patient
hiv
infect
due
characterist
nelfinavir
becom
one
frequent
prescrib
first
line
proteas
inhibitor
treatment
hivinfect
individu
studi
clearli
shown
nelfinavir
strongli
inhibit
replic
sarscov
vero
cell
safeti
drug
human
alreadi
establish
constitut
advantag
nelfinavir
even
clinic
use
sar
patient
result
suggest
nelfinavir
examin
clinic
treatment
sar
moreov
nelfinavir
might
promis
lead
compound
antisar
drug
